The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.
These tests are critically important because a confirmed diagnosis is required for a patient to begin receiving free treatment through our donation programs – and access to treatment is access to life.
We extend our deepest thanks to the dedicated team at Fred Hutch and the hundreds of physicians and nurses around the world who work tirelessly to support their patients. Thanks to your efforts, we not only met but exceeded our initial goal – testing one new patient per day for an entire year.
Here’s how the patient numbers break down by country:
About Spot On CML
Launched in 2017, Spot On CML is a groundbreaking collaboration between The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries. The initiative utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Tanner Pharma Group will serve as the title sponsor for The Max Foundation’s 2018 campaign “Max Global Experience: Uganda,” an expedition to raise awareness and funds for increased cancer treatment access in Africa.
The Max Foundation has renewed and expanded its treatment-access agreement with Incyte in Europe. The agreement will now provide treatment access for up to 50 patients in Eastern Europe and Central Asia.
Estoril, Portugal– In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize. The International CML Foundation awarded our….
